Literature DB >> 19581111

Associations of circulating TNFalpha and IL-18 with myocardial infarction and cardiovascular risk markers: the Glasgow Myocardial Infarction Study.

Paul Welsh1, Mark Woodward, Ann Rumley, Gordon Lowe.   

Abstract

BACKGROUND: There are a lack of data on the associations of circulating levels of TNFalpha and IL-18 with myocardial infarction (MI), and on the extent of confounding by classical and inflammatory risk markers.
METHODS: We measured TNFalpha and IL-18 in plasma from 446 MI cases and 477 age- and sex-matched controls from North Glasgow.
RESULTS: TNFalpha and IL-18 were elevated in cases compared to controls (TNFalpha medians 0.99 pg/ml [interquartile range 0.65-1.64 pg/ml] versus 0.77 pg/ml [0.52-1.22 pg/ml], p<0.0001; IL-18 medians 287 pg/ml [212-404 pg/ml] versus 271 pg/ml [200-373 pg/ml], p=0.01). IL-18 was moderately associated with HDL cholesterol r=-0.22, triglycerides r=0.16, and BMI r=0.14 (p for all < or =0.003) in the control population, but not among cases. TNFalpha had few associations with classical risk factors among cases or controls. TNFalpha had a significant association with MI: odds ratio (OR) 1.66 (95% confidence interval; 1.10-2.50), comparing extreme thirds after adjusting for classical risk factors, which was reduced on further adjustment for other inflammatory markers (OR 1.47; 0.91-2.37). IL-18 showed no association by thirds after adjustment for classical risk factors (OR 1.07; 0.70-1.62).
CONCLUSIONS: Circulating levels of IL-18 and TNFalpha were elevated in those with previous MI, but only TNFalpha retained an association after adjustment for classical risk factors. Independently elevated TNFalpha among those with previous MI may reflect cardiac expression of TNFalpha in ongoing myocardial remodeling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19581111     DOI: 10.1016/j.cyto.2009.06.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  3 in total

1.  Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.

Authors:  Takashi Uzu; Hiroki Yokoyama; Hirofumi Itoh; Daisuke Koya; Atsushi Nakagawa; Makoto Nishizawa; Hiroshi Maegawa; Yukiyo Yokomaku; Shin-Ichi Araki; Atsuko Abiko; Masakazu Haneda
Journal:  Clin Exp Nephrol       Date:  2010-09-09       Impact factor: 2.801

Review 2.  Electroanalytical point-of-care detection of gold standard and emerging cardiac biomarkers for stratification and monitoring in intensive care medicine - a review.

Authors:  Robert D Crapnell; Nina C Dempsey; Evelyn Sigley; Ascanio Tridente; Craig E Banks
Journal:  Mikrochim Acta       Date:  2022-03-12       Impact factor: 6.408

3.  Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study.

Authors:  Barbara J Jefferis; Peter H Whincup; Paul Welsh; S Goya Wannamethee; Ann Rumley; Shah Ebrahim; Debbie A Lawlor; Gordon D O Lowe
Journal:  Cytokine       Date:  2012-12-01       Impact factor: 3.861

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.